In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.
about
CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristicsThe good and evil of complement activation in HIV-1 infectionHumanized mice recapitulate key features of HIV-1 infection: a novel concept using long-acting anti-retroviral drugs for treating HIV-1Current views on the potential for development of a HIV vaccine.Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitopeEvolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies.Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals.Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune SystemEvolution of the HIV-1 env gene in the Rag2-/- gammaC-/- humanized mouse modelDimeric 2G12 as a potent protection against HIV-1.A dimeric form of the HIV-1 antibody 2G12 elicits potent antibody-dependent cellular cytotoxicityInhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody.Full-length haplotype reconstruction to infer the structure of heterogeneous virus populations.Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodiesPartial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation.Clinical development of monoclonal antibody-based drugs in HIV and HCV diseasesDrift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies.Early preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection.In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadthBroadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-LIntercompartmental recombination of HIV-1 contributes to env intrahost diversity and modulates viral tropism and sensitivity to entry inhibitorsBinding of anti-membrane-proximal gp41 monoclonal antibodies to CD4-liganded and -unliganded human immunodeficiency virus type 1 and simian immunodeficiency virus virionsA monoclonal antibody directed against a conformational epitope of the HIV-1 trans-activator (Tat) protein neutralizes cross-cladeMonoclonal antibody-based candidate therapeutics against HIV type 1.Blockage of CD59 Function Restores Activities of Neutralizing and Nonneutralizing Antibodies in Triggering Antibody-Dependent Complement-Mediated Lysis of HIV-1 Virions and Provirus-Activated Latently Infected Cells.N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization.Dose-response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodiesA summary of the workshop on passive immunization using monoclonal antibodies for HIV/AIDS, held at the National Institute of Allergy and Infectious Diseases, Bethesda, 10 March 2006.Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality.In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers.4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response.The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine designRational design of membrane proximal external region lipopeptides containing chemical modifications for HIV-1 vaccination.Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linkedAnti-HIV B Cell lines as candidate vaccine biosensors.Dendritic cells preferentially transfer CXCR4-using human immunodeficiency virus type 1 variants to CD4+ T lymphocytes in transMonoclonal antibodies for prophylaxis and therapy of infectious diseases.Conservation, Compensation, and Evolution of N-Linked Glycans in the HIV-1 Group M Subtypes and Circulating Recombinant Forms.Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN.Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs
P2860
Q21090521-E3AEBB92-7E50-4CC8-B56C-A69EE6E47455Q28275986-073A10C0-42B2-44A4-B5C3-AE324054A1ABQ28728527-251C3245-9788-46B2-ACEF-DF479B38CB0FQ30397595-7BC8B3AD-842A-4F77-98BC-7674F7FDD537Q33417195-D8888DE3-995B-40F3-86F1-A0BD020A7610Q33518005-5FD4EEBE-7FE3-4E73-B923-9036E1536965Q33526340-9E41DC08-DEA6-4894-A4E5-B7A7409DDB91Q33592852-CDFFDCC5-8EC1-4FAC-8D1C-641F5E3B5356Q33676640-10B8EAF4-CF66-465A-860B-1695809E5900Q33780961-9533DC5F-1A12-40C3-A5D6-8D4D5F5561FCQ33969383-17CD109F-3B46-4F99-AEBC-BFB537FFE2C9Q33990484-EE63741C-C10D-4B5B-A7EE-EDDD8C689031Q34044256-37766937-8F39-494B-8537-F79263A6B66EQ34229664-223E8C47-5395-4CA4-9462-9602166DB1DCQ34309493-9C5E1DFC-3E8C-450E-AAA9-460DC0C7216FQ34536782-578D26E4-2232-48E7-BAF5-838D0EF49724Q34594036-30F36FF7-13B5-4725-815A-AADF2A8A16ADQ34594726-4ACB71DD-0044-42FF-9721-7B52C1B4802EQ34937404-5D71F469-2F0B-4481-A339-F7B897367A71Q35012462-B30B04C3-83FD-49F9-B977-0A0D427837E2Q35076953-AB5E0B89-D2B5-43F5-A8E2-7D42B4040AF4Q35689608-96C411DF-2853-4AAA-9B2B-2B193243E7F4Q35874415-7AAC010E-A5F5-4755-810E-06598559ADBDQ35904501-CAA3CCC4-2DBB-4A72-9086-B02BF78FABE2Q35973601-D47C3EC7-4766-4F44-BEF9-738079AD6A3CQ36099045-503C10C5-ED3D-475A-AEA7-282561BEC4B2Q36105672-5CDD8706-4801-4973-812D-14D53DD1B8EBQ36247783-86BD729B-7AFE-4355-937C-C9F175F137DEQ36298503-CE73BC03-28B7-4DCA-8D9E-29BC1A759D91Q36424125-4022C82C-602A-44C0-BE51-BD80EE2F23E1Q36483956-D127E5CD-4029-471C-8203-D87F0F414E88Q36497712-01C8C712-1576-4F05-83D1-D27664E8EB57Q36504833-E5F3D96A-6870-4158-9266-BE7506BA58FDQ36540060-80936074-39B4-4237-A35C-DE8203B783C3Q36766704-C26F73F6-E065-44E4-9A5F-86AC83498F0FQ36845632-D7AFBC1C-0A39-4EFE-B043-A908BCC54448Q36989900-0CA2757A-F72B-45F4-843B-B9ECF983D586Q37153097-EAA72B49-4EE7-4BA9-A38C-5C5DD5C4ACC8Q37208595-6562CB33-BEBE-4368-B1BB-5CEEF1195F4FQ37233074-D90DAEC7-2034-494A-9A2E-F14F82F8DC77
P2860
In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.
@ast
In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.
@en
type
label
In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.
@ast
In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.
@en
prefLabel
In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.
@ast
In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.
@en
P2093
P2860
P50
P356
P1433
P1476
In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.
@en
P2093
Amapola Manrique
Barbara Niederöst
Christine Leemann
Gabriela Stiegler
Hermann Katinger
Marek Fischer
Peter Rusert
Rainer Weber
P2860
P304
P356
10.1128/JVI.00598-07
P407
P577
2007-06-13T00:00:00Z